Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin Versus Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0) and IIIb (T3N2) Gastric Adenocarcinoma

NCT02560974 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02560974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02560974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin Versus Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0) and IIIb (T3N2) Gastric Adenocarcinoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2006
Completion date
November 30, 2012
Enrollment
1,035 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer